AstraZeneca PLC Q3 2025 Earnings Recap

AZN Q3 2025 November 8, 2025

Get alerts when AZN reports next quarter

AstraZeneca continues its strong growth trajectory, reporting an 11% revenue increase year-to-date, fueled by robust demand for its innovative drugs and significant advancements in its pipeline.

Earnings Per Share Beat

$2.38 vs $2.29 est.

+3.9% surprise

Revenue Miss

15191000000 vs 15424376440 est.

-1.5% surprise

Market Reaction

1-Day +0.17%

5-Day +0.2%

30-Day +3.25%

See AZN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Core EPS rose by 15%, reflecting sustained operational momentum.
The company achieved 31 regulatory approvals this year, underscoring an accelerating pipeline.
Growth was broad-based, with oncology revenue up 16% and substantial advances in Biopharmaceuticals and Rare Diseases.
AstraZeneca secured a landmark pricing agreement in the U.S., expected to enhance accessibility and market stability.
Strong performance across key geographies, particularly the U.S. and emerging markets, which saw revenue increases of 11% and 21%, respectively.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AZN on AllInvestView.